Market revenue in 2023 | USD 8.6 million |
Market revenue in 2030 | USD 14.4 million |
Growth rate | 7.6% (CAGR from 2023 to 2030) |
Largest segment | Adeno-associated virus (aav) |
Fastest growing segment | Adeno-associated virus (AAV) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Adeno-associated virus (AAV), Lentivirus, Retrovirus, Adenovirus |
Key market players worldwide | Oxford Biomedical Research, Lonza Group Ltd, Thermo Fisher Scientific Inc, Biogen Inc, Roche Holding AG, Regenxbio Inc, UniQure NV, Bayer AG, Sanofi SA, Batavia Biosciences |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to viral vector market will help companies and investors design strategic landscapes.
Adeno-associated virus (aav) was the largest segment with a revenue share of 51.16% in 2023. Horizon Databook has segmented the Norway viral vector market based on adeno-associated virus (aav), lentivirus, retrovirus, adenovirus covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway viral vector market , including forecasts for subscribers. This country databook contains high-level insights into Norway viral vector market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account